A Device or A Counterfeit Device, That Is The Question

The US FDA has drafted a guidance clarifying its definition of device and counterfeit device to conform with the 2020 Safeguarding Therapeutics Act.

An FDA inspector at the International Mail Facility in New York on 5 March, 2018, inspecting imports for counterfeit products
An FDA inspector at the International Mail Facility in New York on 5 March, 2018, inspecting imports for counterfeit products • Source: Alamy

The US Food and Drug Administration is clarifying the definition of medical devices in a draft guidance based on recent legislative updates. The agency is making the move to exert its Congressional authority to destroy counterfeit devices.

The FDA published the draft guidance, “Referencing the Definition of 'Device' in the Federal Food, Drug and Cosmetic Act...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Have Your Say On EU Digital Regulation Overkill

 

European Commission is expected to have tsunami of responses, including from medtech stakeholders to its public consultation. The US is already intensely interested in developments.

EU Data Act Applies From Today: But Medtech Wants Delay

 

The unwieldy application demands of the EU’s bunch of interconnected data regulations are creating headaches for the medtech industry.

Unified Agenda Rescinds LDT Rule, Sets Few New Priorities

 
• By 

The newly released Unified Agenda, which outlines actions the executive branch plans to take in the coming months, includes several medtech-related proposals.

‘Long-Overdue’ Reforms On Patient Data Sharing Will Help Physicians Deliver Better Care, AMA Says

 

The American Medical Association says years of advocacy have resulted in Medicare policy changes that are a big win for physicians and patients.

More from Policy & Regulation

Blood Sugar Spike Risk Leads To Recall Of Tandem Insulin Pumps

 

Tandem Diabetes Care initiated a recall last month of several t:slim X2 insulin pumps due to a “malfunction 16” error that can cause the pumps to shut down. The problem is triggered by wiring within the device speaker.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

From Prioritizing Funding To Non-Animal Data, FDA Receives A Range Of Comments

 

The US FDA received over two dozen comments from stakeholders on the next round of the medical device user fee amendments, which will establish funding for fiscal years 2028 through 2032.